Melt-blown and electrospun drug-loaded polymer fiber mats for dissolution enhancement: A comparative study

Journal of Pharmaceutical Sciences

Volumn 104, Issue 5, 2015, Pages 1767-1776

  Balogh, Attila ^a   Farkas, Balázs ^a   Faragó, Kornél ^a   Farkas, Attila ^a   Wagner, István ^a   Van Assche, Ivo ^b   Verreck, Geert ^b   Nagy, Zsombor K ^a   Marosi, György ^a  

^a BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Continuous pharmaceutical manufacturing; Electrospinning; Enhanced dissolution rate; Extrusion; HPLC; Melt blowing; Melt electrospinning; Oral drug delivery; Solid dispersion; Viscosity

Indexed keywords

CARVEDILOL; COPOLYMER; MACROGOL 3000; NANOFIBER; POLYMER; SOLVENT; UNCLASSIFIED DRUG; VINYLPYRROLIDONE VINYL ACETATE COPOLYMER; WATER; DRUG; DRUG CARRIER;

ARTICLE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ELECTROSPINNING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; IN VITRO STUDY; MELT BLOWING; MELTING POINT; MOLECULAR WEIGHT; PH; PHYSICAL CHEMISTRY; POLYMERIZATION; SCANNING ELECTRON MICROSCOPY; SOLVENT BASED ELECTROSPINNING; SURFACE PROPERTY; VISCOMETRY; X RAY DIFFRACTION; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; SOLUBILITY; SYNTHESIS;

CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84926304260     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24399     Document Type: Article

References (51)

1. Nagy ZK, Balogh A, Vajna B, Farkas A, Patyi G, Kramarics Á, Marosi G. 2011. Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved dissolution. J Pharm Sci 101:322-332.
2. Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. 2003. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm Res 20:810-817.
3. Yu DG, Xu Y, Li Z, Du LP, Zhao BG, Wang X. 2014. Coaxial electrospinning with mixed solvents: From flat to round Eudragit L100 nanofibers for better colon-targeted sustained drug release profiles. J Nanomater. http://www.hindawi.com/journals/jnm/2014/967295/abs/.
4. Nagy ZK, Nyúl K, Wagner I, Molnár K, Marosi G. 2010. Electrospun water soluble polymer mat for ultrafast release of Donepezil HCl. Express Polym Lett 4:763-772.
5. Vrbata P, Berka P, Stránská D, Doležal P, Musilová M, Čižinská L. 2013. Electrospun drug loaded membranes for sublingual administration of sumatriptan and naproxen. Int J Pharm 457:168-176.
6. Kaassis AYA, Young N, Sano N, Merchant HA, Yu DG, Chatterton NP, Williams GR. 2014. Pulsatile drug release from electrospun poly(ethylene oxide)-sodium alginate blend nanofibres. J Mater Chem B 2:1400-1407.
7. Nagy ZK, Wagner I, Suhajda A, Tobak T, Harasztos AH, Vigh T, Soti PL, Pataki H, Molnar K, Marosi G. 2014. Nanofibrous solid dosage form of living bacteria prepared by electrospinning. Express Polym Lett 8:352-361.
8. Keseru GM, Makara GM. 2009. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8:203-212.
9. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol 44:235-249.
10. Sastry SV, Nyshadham JR, Fix JA. 2000. Recent technological advances in oral drug delivery - A review. Pharm Sci Technol 3:138-145.
11. Langer R. 1993. Polymer-controlled drug delivery systems. Accounts Chem Res 26:537-542.
12. Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
13. Liu YY, Li QW, Hu QX, Jing CJ, Wang QG. 2011. A new spurts controllable electrospinning collecting device designed basing on advanced motion control. Appl Mech Mater 44-47:1698-1702.
14. Nagy ZK, Balogh A, Drávavölgyi G, Ferguson J, Pataki H, Vajna B, Marosi G. 2012. Solvent-free melt electrospinning for preparation of fast dissolving drug delivery system and comparison with solvent-based electrospun and melt extruded systems. J Pharm Sci 102:508-517.
15. Patyi G, Bodis A, Antal I, Vajna B, Nagy ZK, Marosi G. 2012. Thermal and spectroscopic analysis of inclusion complex of spironolactone prepared by evaporation and hot melt methods. J Therm Anal Calorim 102:349-355.
16. Sauceau M, Fages J, Common A, Nikitine C, Rodier E. 2010. New challenges in polymer foaming: A review of extrusion processes assisted by supercritical carbon dioxide. Prog Polym Sci 36:749-766.
17. Grohganz H, Priemel PA, Löbmann K, Nielsen LH, Laitinen R, Mullertz A, Mooter GV, Rades T. 2014. Refining stability and dissolution rate of amorphous drug formulations. Expert Opin Drug Deliv 11:977-989.
18. 2-aided and conventional melt extrusion for enhancing the dissolution rate of an active pharmaceutical ingredient. Polym Advan Technol 23:909-918.
19. Moulton SE, Wallace GG. 2014. 3-dimensional (3D) fabricated polymer based drug delivery systems. J Control Release 193:27-34.
20. Maniruzzaman M, Boateng JS, Snowden MJ, Douroumis D. 2012. A review of Hot-melt extrusion: Process technology to pharmaceutical products. ISRN Pharm. http://www.hindawi.com/journals/isrn/2012/436763/abs/.
21. Foster A, Hempenstall J, Tucker I, Rades T. 2001. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 226:147-161.
22. Li HY, Bubakir MM, Xia T, Zhong XF, Ding YM, Yang WM. 2014. Mass production of ultra-fine fibre by melt electrospinning method using umbellate spinneret. Mater Res Innov 18(S4):921-925.
23. Wang Q, Curtis CK, Thoppey NM, Bochinski JR, Gorga RE, Clarke LI. 2014. Unconfined, melt edge electrospinning from multiple, spontaneous, self-organized polymer jets. Mater Res Exp 1:045304.
24. Petrik S, Maly M. 2009. Production nozzle less electrospinning nanofiber technology. Mat Res S 1240:7-18.
25. Persano L, Camposeo A, Tekmen C, Pisignano D. 2013. Industrial upscaling of electrospinning and applications of polymer nanofibers: A review. Macromol Mat Eng 298:504-520.
26. Nagy ZK, Balogh A, Démuth B, Pataki H, Vigh T, Szabó B, Molnár K, Schmidt BT, Horák P, Marosi G, Verreck G, Van Assche I, Brewster ME. 2015. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm 480:137-142.
27. Luo CJ, Stoyanov SD, Stride E, Pelan E, Edirisinghe M. 2012. Electrospinning versus fibre production methods: From specifics to technological convergence. Chem Soc Rev 41:4708-4735.
28. Hutmacher DW, Dalton PD. 2011. Melt electrospinning. Chem Asian J 6(1):44-56.
29. Bresse RR, Ko WC. 2003. Fiber formation during melt blowing. Int Nonwowens J Summer 2003:21-28.
30. Shaumbaugh RL. 1988. A macroscopic view of the melt-blowing process for producing microfibers. Ind Eng Chem Res 27:2363-2372.
31. Ellison CJ, Phatak A, Giles DW, Macosko CW, Bates FS. 2007. Melt blown nanofibers: Fiber diameter distributions and onset of fiber breakup. Polymer 48:3306-3316.
32. Balogh A, Drávavölgyi G, Faragó K, Farkas A, Vigh T, Sóti PL, Wagner I, Madarász J, Pataki H, Marosi G, Nagy ZK. 2014. Plasticized drug-loaded melt electrospun polymer mats: Characterization, thermal degradation and release kinetics. J Pharm Sci 103(4):1278-1287.
33. Loftsson T, Vogensen SB, Desbos C, Jansook P. 2008. Carvedilol: Solubilization and cyclodextrin complexation: A technical note. AAPS Pharm Sci Tech 9(2):425-430.
34. Sugawara M, Kadomura S, He X, Takekuma Y, Kohri N, Miyazaki K. 2005. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Eur J Pharm Sci 26:1-8.
35. Fordtran JS, Walsh JH. 1973. Gastric acid secretion rate and buffer content of the stomach after eating. J Clin Invest 52:645-657.
36. Davis ME, Brewster ME. 2004. Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov 3:1023-1035.
37. Deering TB, Malagelada JR. 1977. Comparison of an H2 receptor antagonist and a neutralizing antacid on postprandial acid delivery into the duodenum in patients with duodenal ulcer. Gastroenterology 73:11-14.
38. Deering TB, Carlson GL, Malagelada UR, Duenes HA, McCall JT. 1979. Fate of oral neutralizing antacid and its effect on postprandial gastric secretion and emptying. Gastroenterology 77:986-990.
39. Weitschies W, Kosch O, Mönnikes H, Trahms L. 2005. Magnetic marker monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv Drug Deliv Rev 57:1210-1222.
40. Rathore MM. 2010. Thermal engineering. New Delhi, India: Tata McGraw Hill, pp 298-331.
41. Stojanović J, Vladimirovm S, Marinković V, Velićković D, Sibinović P. 2007. Monitoring of the photochemical stability of carvedilol and its degradation product by the RP-HPLC method. J Serb Chem Soc 72:37-44.
42. Janssens S, Nagels S, Armas HN, D'Autry W, Schepdael AV, Mooter GV. 2007. Formulation and characterization of ternary solid dispersions made up of itraconazole and two excipients, TPGS and PVPVA 64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 69(1):158-166.
43. Drooge DJ, Hinrichs WLJ, Visser MR, Frijlink HW. 2006. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meters scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J Pharm 310:220-229.
44. Zhou H, Green TB, Joo YL. 2006. The thermal effects on electrospinning of polylactic acid melts. Polymer 8:7497-7505.
45. Gu SY, Ren J, Wu QL. 2005. Preparation and structures of electrospun PAN nanofibers as a precursor of carbon nanofibers. Synthetic Met 155:157-161.
46. Hassan MA, Yeom BY, Wilkie A, Pourdeyhimi B, Khan SA. 2013. Fabrication of nanofiber meltblown membranes and their filtration properties. J Membr Sci 427:336-344.
47. Pielichowski K, Flejtuch K. 2002. Differential scanning calorymetry studies on poly(ethylene glycol) with different molecular weights for thermal energy storage materials. Polym Adv Technol 13:690-696.
48. International conference on harmonisation. 2006. Note for guidance on impurities in new drug products.
49. Rickli H, Steiner S, Müller K, Hess OM. 2003. Betablockers in heart failure: Carvedilol safety assessment (CASA 2-trial). Eur J Heart Fail 6:761-768.
50. Pharmacopoea Europaea 7.0, pp 1595-1596.
51. Lanzanova FA, Argenta D, Arend MZ, Junior LB, Cardoso SG. 2009. LC and LC-MS evaluation of stress degradation behavior of carvedilol. J Liq Chromatogr R T 32(4):526-543.